David Leffell

Catalogued medical knowledge doubles every 73 days. At DocMatter, we enable physicians to harness the power of these big data sets to deliver the best possible patient outcomes. DocMatter is an AI-driven digital health company that has developed an online, peer-to-peer collaboration platform that streamlines knowledge access across a global network of highly-engaged healthcare professionals. Every physician has a unique combination of experiences, expertise and interests and DocMatter provides them with a time-saving platform to discover, share and learn. The problems we address are profound: - Medical error is the third leading cause of death in the US (Johns Hopkins) - Only 55% of patient case treatment algorithms follow recommended care standards (NEJM) - Once new clinical data proving superior patient outcomes for a medical product is released, it takes ~17 years for standards of care to change (World Bank) - Tens of billions of dollars are spent every year on SG&A by the healthcare industry getting new and innovative medical products in front of doctors (E&Y) - The US spends more than $10,000 per individual or 18% of GDP on healthcare, with estimates nearing $1 trillion dollars in total waste (JAMA) DocMatter provides physicians with actionable insights that every day lead to life-changing outcomes for patients around the world. We are scaling fast, come join us!

Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body’s response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. The Company’s lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.

Skinosive is a science-driven dermo-cosmetics biotechnology company developing a technology platform in skin photoprotection. Skinosive’s technology enables long lasting skin UV protections and effective sunscreens that prevent chemicals from being absorbed into the skin and the bloodstream. This innovation aims to reduce drastically cancer and skin damages due to the sun exposure. The company is located in Paris and in Marseille. Skinosive Headquarter : 53 rue de Turbigo 75003 Paris Skinosive Lab : 60 avenue André Roussin 13016 Marseille

Connecticut Public Television is a broadcast media company based out of 1049 ASYLUM AVE, Hartford, Connecticut, United States.

Catalogued medical knowledge doubles every 73 days. At DocMatter, we enable physicians to harness the power of these big data sets to deliver the best possible patient outcomes. DocMatter is an AI-driven digital health company that has developed an online, peer-to-peer collaboration platform that streamlines knowledge access across a global network of highly-engaged healthcare professionals. Every physician has a unique combination of experiences, expertise and interests and DocMatter provides them with a time-saving platform to discover, share and learn. The problems we address are profound: - Medical error is the third leading cause of death in the US (Johns Hopkins) - Only 55% of patient case treatment algorithms follow recommended care standards (NEJM) - Once new clinical data proving superior patient outcomes for a medical product is released, it takes ~17 years for standards of care to change (World Bank) - Tens of billions of dollars are spent every year on SG&A by the healthcare industry getting new and innovative medical products in front of doctors (E&Y) - The US spends more than $10,000 per individual or 18% of GDP on healthcare, with estimates nearing $1 trillion dollars in total waste (JAMA) DocMatter provides physicians with actionable insights that every day lead to life-changing outcomes for patients around the world. We are scaling fast, come join us!

Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body’s response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. The Company’s lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.

Skinosive is a science-driven dermo-cosmetics biotechnology company developing a technology platform in skin photoprotection. Skinosive’s technology enables long lasting skin UV protections and effective sunscreens that prevent chemicals from being absorbed into the skin and the bloodstream. This innovation aims to reduce drastically cancer and skin damages due to the sun exposure. The company is located in Paris and in Marseille. Skinosive Headquarter : 53 rue de Turbigo 75003 Paris Skinosive Lab : 60 avenue André Roussin 13016 Marseille

Tullis Health Investors manages a family of funds and investments, each focused exclusively on healthcare. Founded in 1986, Tullis currently manages three funds focused geographically on North America. The Tullis team has broad and deep experience in healthcare investing and a track record of top-quartile performance.